Biogen Idec, Inc. (Massachusetts) And Elan Corporation PLC TYSABRI(R) Two-Year Phase III Multiple Sclerosis Clinical Trial Results And Safety Evaluation Published In New England Journal Of Medicine; TYSABRI Currently Under Review With U.S. And European Re

CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--March 1, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that two-year results from the two Phase III clinical trials evaluating TYSABRI(R) (natalizumab) for patients with relapsing forms of multiple sclerosis (MS), as well as data from the comprehensive safety evaluation of the product were published for the first time in this week's issue of The New England Journal of Medicine. The two-year data from the Phase III MS trials were previously presented at U.S. and international medical meetings during 2005.

Back to news